Señales en vivo de INFI | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 sept 2023 @ 15:59):

Stats
Volumen de hoy	2.48M
Volumen promedio	3.98M
Capitalización de mercado	726 089
EPS	$0 ( 2024-03-26 )
Próxima fecha de ganancias	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0182
ATR14	$0.00900 (230.77%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-09	Perkins Adelene Q	Buy	768 133	Common Stock
2023-09-12	Perkins Adelene Q	Sell	410 196	Common Stock
2023-09-09	Perkins Adelene Q	Sell	768 133	Restricted Stock Unit
2022-08-02	Peluso Stephane	Buy	14 994	Common Stock
2022-08-02	Peluso Stephane	Sell	50 000	Restricted Stock Unit

INSIDER POWER
-17.21
Last 96 transactions
Buy: 10 433 668 \| Sell: 9 549 867

Volumen Correlación

Largo: 0.01 (neutral)

Corto: 0.15 (neutral)

Signal:(27.787) Neutral

Infinity Pharmaceuticals Correlación

10 Correlaciones Más Positivas
TTOO	0.944
IMPL	0.942
VNET	0.938
AVIR	0.933
EGAN	0.931
STAF	0.924
TUEM	0.924
AZYO	0.921
JD	0.92
BGFV	0.92

10 Correlaciones Más Negativas
TA	-0.959
TYHT	-0.937
SERA	-0.936
SYKE	-0.933
RDUS	-0.927
CPTA	-0.924
XLRN	-0.923
ICON	-0.923
ZGNX	-0.92
PAE	-0.915

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Infinity Pharmaceuticals Correlación - Moneda/Commodity

-0.46
( neutral )

-0.80
( strong negative )

0.00
( neutral )

-0.32
( neutral )

0.74
( moderate )

Infinity Pharmaceuticals Finanzas

Annual	2022
Ingresos:	$2.59M
Beneficio Bruto:	$1.03M (39.72 %)
EPS:	$-0.480

FY	2022
Ingresos:	$2.59M
Beneficio Bruto:	$1.03M (39.72 %)
EPS:	$-0.480

FY	2021
Ingresos:	$1.86M
Beneficio Bruto:	$738 000 (39.72 %)
EPS:	$-0.530

FY	2020
Ingresos:	$1.72M
Beneficio Bruto:	$682 000 (39.67 %)
EPS:	$-0.680

Financial Reports:

No articles found.

Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.

Actualizaciones en tiempo real para Infinity Pharmaceuticals [INFI]

Upcoming Earnings Alert